Business context and reporting period
HUTCHMED (China) Ltd. (then Hutchison China MediTech Limited) filed this Form 20-F for the fiscal year ended December 31, 2019. It is an annual report, not a standalone 2019 Q4 report; the filing text does not provide clear standalone fourth-quarter financial results. The company reports under U.S. GAAP and operates an Innovation Platform focused on drug research and development and a China-focused Commercial Platform. Amounts below are in U.S. dollars; financial figures are in millions unless stated otherwise.
Financial and operating highlights
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $204.9 | $214.1 | Down 4.3% |
| Cost of sales | $160.2 | $143.9 | Up 11.3% |
| Research and development expense | $138.2 | $114.2 | Up 21.0% |
| Operating loss before other income, tax and equity earnings | $(146.4) | $(92.6) | Loss widened |
| Net loss | $(103.7) | $(71.3) | Loss widened |
| Net loss attributable to the company | $(106.0) | $(74.8) | Loss widened |
| Operating cash flow | $(80.9) | $(32.8) | Cash use increased |
| Capital expenditures | $8.6 | $6.4 | Up |
Gross profit was approximately $44.7 million, or a 21.8% gross margin, compared with approximately $70.2 million, or 32.8%, in 2018. The deterioration reflected higher cost of sales and a changed sales mix. Net margin was approximately negative 50.6%, versus negative 33.3% in 2018. Equity-method earnings from joint ventures were $40.7 million, up from $19.3 million, and substantially offset the company’s operating loss.
Commercial Platform revenue increased 7.0% to $188.9 million; Innovation Platform revenue fell 57.4% to $16.0 million, mainly because 2018 included a $13.5 million fruquintinib milestone payment and 2019 had lower Nutrition Science Partners service fees. Fruquintinib generated $10.8 million of 2019 revenue, including $2.7 million in royalties and $8.1 million in product sales to Eli Lilly at cost.
Liquidity, debt and balance sheet
At December 31, 2019, cash and cash equivalents were $121.2 million and short-term investments were $96.0 million, totaling $217.2 million. Current assets were $317.0 million and current liabilities $113.1 million. Total assets were $465.1 million; total liabilities were $152.2 million; and shareholders’ equity was $312.9 million. Bank borrowings were $26.8 million, due in 2022; unused bank facilities were approximately $119.4 million. The filing states that available cash, investments, expected operating cash flows and facilities were expected to fund operations and commitments for at least 12 months, subject to assumptions that could prove incorrect. Non-consolidated joint ventures held an additional $62.7 million in cash, but those funds are accessible to HUTCHMED only through distributions.
Material changes versus the prior comparable period
- Revenue declined despite growth in the Commercial Platform, as collaboration and licensing revenue fell and sales of Seroquel ended in May 2019. Management reported a $21.9 million decline in Seroquel revenue after Luye Pharma Hong Kong purported to terminate the distribution arrangement.
- Research and development spending rose as clinical programs and staffing expanded. The increase in clinical trial costs and compensation contributed to a wider Innovation Platform loss.
- Higher cost of sales, combined with lower revenue, reduced gross margin. Commercial Platform cost of sales rose faster than its revenue.
- Equity earnings increased partly because 2018 included HUTCHMED’s $15.0 million share of Nutrition Science Partners’ $30.0 million intangible-asset impairment. HUTCHMED acquired the partner’s 50% interest in that venture on December 9, 2019 for approximately $8.1 million, after which it became consolidated; the venture had no operating activity in 2019.
- Cash and short-term investments together were $217.2 million at year-end, while operating cash use rose to $80.9 million from $32.8 million.
Outlook, commentary, risks and unusual items
Management planned continued clinical investment and stated that R&D expenses were expected to increase as programs advanced. As of the filing date, it expected to initiate global registration studies for fruquintinib and surufatinib in 2020, and anticipated potential China launch preparations for surufatinib following positive Phase III results in neuroendocrine tumors. These are forward-looking plans, not guarantees. Fruquintinib was added to China’s National Reimbursement Drug List effective January 1, 2020, at a 63% discount to its initial retail price.
Material risks include clinical-trial and regulatory uncertainty, the possibility that drug candidates fail to obtain approval or commercial acceptance, rising development and commercialization costs, reliance on collaboration partners and joint ventures for development funding and dividends, reimbursement and pricing pressure, and dependence on third-party suppliers. The company also cited China operating and foreign-exchange restrictions, currency translation exposure, and the early effects of COVID-19: limits on clinical-study visits and short-term disruption to sales-team activity. Management cautioned that the duration and effect of the outbreak were uncertain.
The Seroquel distribution dispute remained in litigation; management believed Luye lacked grounds to terminate and recorded no adjustment to related balances. The auditor identified the valuation of Seroquel-related balances and the principal-versus-agent revenue assessment as critical audit matters. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The filing reported no other material legal proceedings pending or threatened to the company’s knowledge. HUTCHMED reported no dividend payments and no current plan to pay dividends.
After year-end, HUTCHMED issued shares represented by ADSs for gross proceeds of $110.0 million in January 2020 and an additional $8.3 million in February 2020. This subsequent financing is not included in the December 31, 2019 balance sheet.
Important facts for investors to verify
- Confirm the absence of standalone Q4 2019 figures before comparing the annual results with quarterly estimates.
- Check current fruquintinib sales, royalty economics, reimbursement-driven price and volume effects, and the terms under which HUTCHMED may gain promotion and distribution rights.
- Track surufatinib regulatory decisions and launch timing, and verify enrollment, results and regulatory status for key clinical programs.
- Review the Seroquel dispute’s outcome and any resulting asset, liability, revenue or cash-flow adjustments.
- Assess cash burn against the stated 12-month liquidity outlook, including access to joint-venture dividends and the use of the 2020 financing proceeds.
- Verify supplier redundancy for clinical and commercial drug materials, and monitor the effect of COVID-19 and other regulatory or market changes on trials and sales.